Zenith Epigenetics
  • About
  • Science & Epigenetics
  • Programs
  • Newsroom
  • Contact
  • Connect
    Email
    info@zenithepigenetics.com
    Call
    1 (587) 390-7865
    Share
  • FAQ
Newsroom
  • News Releases
  • Presentations & Events
  • SEDAR Filings

News Releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
May 10, 2022
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
January 31, 2022

About

  • Overview
  • Management
  • Board of Directors

Science & Epigenetics

  • What is Epigenetics?
  • BET Inhibitors & Oncology
    • Resistance & Combo Therapy
  • BET Inhibitor Platform
    • Covalent BET Inhibitors
    • Translational Medicine
  • Publications & Posters

Programs

  • Oncology Pipeline
    • Prostate Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Other Solid Tumor Cancers
  • Partnerships & Collaborations

Newsroom

  • News Releases
  • Presentations & Events
  • SEDAR Filings

Contact

  • Contact
  • Careers
  • Shareholder FAQ

© 2022 zenithepigenetics | Legal | Privacy

Bookmark and Share